英国当局调查辉达收购Arm有否违反竞争法
英国竞争与市场管理局(CMA)已经对辉达(Nvidia)(NVDA.US)以400亿美元收购英国晶片设计商Arm展开调查,之前Arm行政总裁Simon Segars在去年9月与辉达达成交易时已承认,要获得全球监管机构的批准可能需时18个月。
Arm设计用於智能手机、电脑及平板电脑的晶片方面上处於全球领先地位,CMA表示,晶片技术行业价值属数以十亿美元计,对於日常生活中有重要作用,该局将与全球其他竞争监管机构紧密合作,仔细考虑交易所有的潜在影响,并确保最终不会导致消费者承受价格更高或质量下降的产品。
CMA续指,将研究交易对英国竞争环境的潜在影响,如果调查发现交易违反英国竞争规则,CMA可阻止今次收购。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.